LRI Investments’s Recursion Pharmaceuticals RXRX Stock Holding History

LRI Investments’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-111	Closed	-$454	–	1491
2025 Q4	$454	Buy	+111	New	+$550	﹤0.01%	1319

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LRI Investments's RXRX Position: Q1 2026 in Review

LRI Investments sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 111 shares — an estimated $454 sold.

LRI Investments first reported a position in RXRX in Q4 2025 and held it in 1 quarter. The position peaked at $454 in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

LRI Investments reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
LRI Investments sold 111 Recursion Pharmaceuticals shares in Q1 2026, an estimated $454.
LRI Investments first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 1 quarter.
LRI Investments's Recursion Pharmaceuticals position peaked at $454 in Q4 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on LRI Investments's 13F filing for Q1 2026, filed 30 Apr 2026.